In an interview with E24, board member and investor representative for TD Veen, Øyvind G. Schanke, and regional director at Axon, Lowan Steward, provide more insight to the company.
Axon offers Ketamine-Assisted Psychotherapy (KAP), a treatment method that combines psychotherapy with repeated ketamine treatments. The company is the leading ketamine clinic in the Nordic region.
“The financial return is not what primarily attracts the investors we have brought on board. It is the fact that we can make a difference”, says Schanke in the interview with E24.
Regional director Steward, who has been involved in establishing the ketamine offering at Østfold Hospital believes that both private and public offerings are important:
“Our vision has always been to increase access to ketamine treatment for as many as possible. Many need treatment for free through the public system, but there are also many willing to pay for the treatment”, he says.
Read the full article on E24 (in Norwegian).
See more news